Real-World data may reveal Pluvicto's true impact on advanced prostate cancer survival

NCT ID NCT07697989

First seen Jul 13, 2026 · Last updated Jul 23, 2026 · Updated 3 times

Summary

This study looks at how effective the drug Pluvicto (177Lu-PSMA-617) is in treating men with a type of advanced prostate cancer that no longer responds to hormone therapy and has spread to other parts of the body. Researchers will analyze medical records from over 1,000 patients in the United States and Germany to measure survival times and other outcomes. The goal is to see how well the drug works outside of controlled clinical trials, in everyday medical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Pluvicto (177Lu-PSMA-617)
What this could lead to
If successful, this study could confirm that Pluvicto improves survival in a broad, real-world population of men with advanced prostate cancer, supporting its use in routine care.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by patient selection or other treatments. Effectiveness may vary across different patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.